Mevopur™ Healthcare Colorants and Formulations Mevopur™ Healthcare Functional Additives Mevopur™ Healthcare Bio-based Polymer Solutions

We also navigate the complex regulatory landscape, helping you meet the latest safety and compliance standards.  Mevopur™ Healthcare Colorants and Formulations Mevopur™ Healthcare Functional Additives

Mevopur™ Healthcare Colorants and Formulations Special Effect Colorants for Healthcare Devices and Pharmaceutical Packaging Self-administered medication, for example via pen devices and inhalers, has been the norm for many years. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

FDA/EU compliance information available upon request Mevopur™ Healthcare Colorants and Formulations for Ophthalmic Closures The Mevopur™ range of standard concentrates for closures used with ocular (ophthalmic) medicines matches the color standards from the American Academy of Ophthalmology (AAO). As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Mevopur™ Healthcare Functional Additives for Pharmaceutical Packaging Mevopur™ Healthcare Functional Additives help protect and enhance the performance of polymers used in pharmaceutical packaging products such as vials, bottles, closure systems, films and combination devices. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Mevopur™ Healthcare Functional Additives for Medical Devices and Diagnostic Equipment Mevopur™ Healthcare Functional Additives help protect and enhance the performance of polymers used in applications, such as medical housings, drug delivery devices, syringes and needles, diagnostics, and catheters. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

We kept safety first, used service as our timeless diff erentiator, and executed our proven four-pillar strategy. We do this through our safety focus, benefits, and lifestyle programs. Environmental, Health and Safety 4.

Mevopur™ Healthcare Bio-based Polymer Solutions for Medical Devices and Pharmaceutical Packaging Manufacturers of medical devices and pharmaceutical packaging are increasingly faced with the challenge of integrating sustainability into the design of their products. As part of our commitment, we publish Avient’s Mevopur™ product policy and use limitations to assist customers in their product selection. For more detailed information on Mevopur uses and restrictions see www.avient.com/healthcare-use-limitations-mevopur-products or contact your Avient sales representative. 1.844.4AVIENT www.avient.com

Avient Corporation 1 JEFFERIES VIRTUAL INDUSTRIALS CONFERENCE A U G U S T 2 0 2 0 Avient Corporation 2 FORWARD LOOKING STATEMENTS Avient Corporation 3 USE OF NON-GAAP MEASURES Avient Corporation 4 UPDATE ON THE COVID-19 PANDEMIC Avient Corporation 5 2019 Transportation Consumer Discretionary Healthcare Packaging All Other Industries Cost Containment FX 2020 $64.3 18% 16% 2% $46.9 SECOND QUARTER 2020 IN REVIEW Consumer Discretionary Avient Corporation 6 CLARIANT MASTERBATCH STRATEGIC RATIONALE Avient Corporation 7 FIT W I T H FOUR PILLAR S T R A T E G Y Specialization Globalization Operational Commercial People Avient Corporation 8 2006 2019E PF* 2006 2019E PF* 38% * 2019E Pro Forma for PP&S Divestiture and Clariant Masterbatch business Percentage of Total Revenue E N D M A R K E T T R A N S F O R M A T I O N Building & Construction High Growth End Markets 50% 22% Avient Corporation 9 Electronic 38% 18%Transportation Building & Constrution Electrial & Electronic 2006 Pro Forma(1) Net Sales by End Market E N D M A R K E T T R A N S F O R M A T I O N Avient Corporation 10 U N I F I E D F O C U S O N S U S T A I N A B I L I T Y 2006 - 2013 2013 – 2019 PEOPLE PROD UC TS PLANET PER FOR M A NC E Avient Corporation 11 O V E R 8 5 % O F A D J U S T E D E B I T D A F R O M S P E C I A L T Y 46% 66% 0% 40% 60% 80% 100% 2005 2010 2015 Pro Forma % o f A d ju s te d E B IT D A ( 1) JVs Performance Products & Solutions Distribution Specialty 87% (2) Avient Corporation 12 T H E N E W A V I E N T : A S P E C I A L T Y G R O W T H C O M P A N Y Transaction expected to add $0.85 to pro forma adjusted EPS Avient Corporation 13 SUSTAINABILITY AT AVIENT P E O P L E , P R O D U C T S , P L A N E T , P E R F O R M A N C E Avient Corporation 13 Avient Corporation 14 V I S I O N To be the world’s premier provider of specialized polymer materials, services and C O R E V A L U E S P E R S O N A L V A L U E S Honesty IntegrityRespect Operational Commercial Specialization Globalization Collaboration ExcellenceInnovation To be the world’s premier provider of specialized polymer materials, services and sustainable Avient Corporation 15 1.3 1.1 1.1 0.85 0.65 0.57 0.54 0.97 0.84 0.74 0.74 0.69 0.51 0.56 0.14 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 YTD S A F E T Y F I R S T Injuries per 100 Workers Spartech Acquisition Avient Corporation 16 G R E A T P L A C E T O W O R K Avient Corporation 17 C O M M O D I T Y T O S P E C I A L T Y T R A N S F O R M A T I O N 2006 - 2013 2013 – 20192000-2005 2006 - 2013 2020 and Beyond Avient Corporation 18 A V I E N T 2 0 1 9 R E V E N U E | $ 2 . 9 B I L L I O N Segment End Market Geography Wire & Cable Building & Electrical & Electronics Color Additives & Inks 34% Distribution 41% Specialty Engineered Materials 25% United States 54% Latin America Avient Corporation 19 Operating Income % of Sales Color, Additives & Inks 1.7% 14.7% Specialty Engineered Materials 1.1% 11.6% Distribution 2.6% 6.3% 2009 2010 2011 2012 2013 2014 2015 2016*2017* 2018 $2.43 P R O O F O F P E R F O R M A N C E C O N S E C U T I V E Y E A R S 10 $0.13 $0.68 $0.82 $1.00 $1.31 $1.80 $1.96 $2.06 $2.21 A D J U S T E D E P S E X P A N S I O N 2018 2019 $1.69 $1.51 Avient Corporation 20 531 710 1,032 130 164 207 504 663 871 2014 2018 Pro Forma R&D / Technical Marketing Sales + 34% + 26% + 32% E X P A N S I O N O F COMMERCIAL RESOURCES D R I V I N G G R O W T H Revenue in Billions Total + 10% Organic + 7%+ 45% + 26% + 31% $4.0 $3.2 (2) (1) (1) $2.9 $2.9 $3.5 2015 2016 2017 2018 Pro Forma Total + 9% Organic + 5% Pro Forma(2) Avient Corporation 21 P R I O R A C Q U I S I T I O N S H I S T O R Y Commercial Resources(1) Operating Income ($ in millions) Operating Margins 256 350 $36 $100 Established Acquisitions (> 7 years) + 37% + 176% + 1000 bps Avient Corporation 22 A L I G N I N G W I T H T R E N D S F O R G R O W T H T R A N S P O R T A T I O N P A C K A G I N G H E A L T H C A R E C O N S U M E R Facilitate alternative energy Light- weighting Reduce packaging materials Improve recyclability Reduce spread of infection Avient Corporation 23 I N N O V A T I O N Customization 55% M&A 30% Innovation Pipeline Innovation comes from Research & Development Spend Vitality Index 37% $20 $51 Avient Corporation 24 R E V E N U E F R O M S U S T A I N A B L E S O L U T I O N S $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth Avient Corporation 25 SEGMENT HIGHLIGHTS I N N O V A T I N G W I T H A V I E N T Avient Corporation 25 Avient Corporation 26 C O L O R , A D D I T I V E S & I N K S E N D M A R K E T S & S O L U T I O N S Solid Colorants Performance Additives Screen Printing Inks Liquid Colorants 31% Building & Construction Appliances Electrical & Electronics Avient Corporation 26 Avient Corporation 27 Operating Income & MarginRevenue by Region C O L O R , A D D I T I V E S & I N K S 2 0 1 9 R E V E N U E | O V E R $ 1 B I L L I O N 34% United States 44% Mexico South America $4 $25 $104 $147 0.9% 5.5% 12.2% 14.7% Avient Corporation 27 Avient Corporation 28 S P E C I A L T Y E N G I N E E R E D M A T E R I A L S E N D M A R K E T S & S O L U T I O N S Engineered Formulations Advanced Composites Thermoplastic Elastomers Wire & Cable* 28% Electrical & Electronics Building & Construction Avient Corporation 28 Avient Corporation 29 S P E C I A L T Y E N G I N E E R E D M A T E R I A L S Revenue by Region Operating Income & Margin 2 0 1 9 R E V E N U E | $ 7 5 0 M I L L I O N 27% United States 54% 17% $21 $57 $87 0.1% 5.1% 9.3% 11.6% Avient Corporation 29 Avient Corporation 30 D I S T R I B U T I O N E N D M A R K E T S & S U P P L I E R S 28% 17% Electrical & Electronics Building & Operating Income & Margin2019 Revenue | $1.2 Billion $25 $63 $75 $20 2.9% 4.0% 5.9% 6.3% Avient Corporation 30 http://www.polyone.com/Pages/VariationRoot.aspx Avient Corporation 31 O V E R V I E W O F R A W M A T E R I A L P U R C H A S E S Avient Corporation 31 Avient Corporation 32 Avient Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax Special items, tax adjustments Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S). Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering Three Months Ended March 31, 2020 Net income from continuing operations – GAAP $ 33.1 Special items, after tax 8.6 After tax interest income earned on equity proceeds, included in Interest expense, net (0.7) Adjusted net income excluding special items and impact of interest income on equity proceeds $ 41.0 Diluted weighted-average shares used to compute earnings per common share 86.7 Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (9.3) Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 77.4 Adjusted EPS - excluding special items and the net impact of equity offering $ 0.53 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to PolyOne shareholders, excluding special items, to assess performance and facilitate comparability of results. Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Avient Investor Presentation - Jefferies Industrials Conference August 2020.pdf August 2020 investor non-GAAP reconciliation.pdf August 2020 investor non-GAAP

If the material is allowed to stay in an injection molding machine or extruder (profile, sheet, etc.) too long, the material will start to discolor and brown ‘freckles’ may appear.  Get the answers to these questions by downloading our PDF Guide to Polyketone overview brochure. Download PDF